Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
NEJM
Biotech
Amylyx's neuron-protecting drug slows ALS decline in NEJM study
After 6 months, Amylyx's AMX0035 demonstrated a significant benefit compared to placebo, delaying the fast-acting neurodegenerative disease.
Conor Hale
Sep 2, 2020 5:00pm
Chasing Biogen, AveXis posts improved gene therapy data
Nov 2, 2017 7:51am
NEJM paper buoys GW Pharma as it eyes FDA filing for Epidiolex
May 25, 2017 9:26am
La Jolla posts mixed bag of phase 3 data
May 22, 2017 5:04am
Gene therapy effective in rare blindness, wet AMD next target
May 4, 2016 2:34am
